2024 Year-In-Review Report: Global Trends in Biopharma Transactions
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings.
Podcast: Play in new window | Download (Duration: 29:41 — 67.9MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Geoff Meyerson, CEO and Co-founder of Locust Walk, speaks with Sudhir Agrawal, Founder and President
In this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, is joined by Andy Meyerson, Managing Director, and Daniel
Podcast: Play in new window | Download (Duration: 34:01 — 77.9MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q3 Report: Global Trends in Biopharma
Podcast: Play in new window | Download (Duration: 26:21 — 60.3MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk’s Andy Meyerson welcomes Dr. Lindsay Rosenwald, Chairman, President and Chief Executive Officer of Fortress Biotech, a company
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter,
LOCUST WALK NEWS CytoReason secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale its AI disease models
LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Pricing of Upsized $153,000,000 Initial Public Offering PHILADELPHIA and BOSTON, Jan. 7,
LOCUST WALK NEWS Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib Ascentage Pharma